FREMONT, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRMLQ) today announced that Gail Page, Vermillion Executive Chairperson, will be presenting at the Lazard Capital Markets Sixth Annual Healthcare Conference in New York City.
The presentation is scheduled for Tuesday, November 17, 2009 at 5:10 p.m. Eastern Time.
About the OVA1 Test
The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
Quest Diagnostics, which is a long-time investor in research and development of the OVA1 technology, has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
SOURCE Vermillion, Inc.
|SOURCE Vermillion, Inc.|
Copyright©2009 PR Newswire.
All rights reserved